AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice are systematically developed statements to assist health care professionals in medical decision-making for specific clinical conditions but are in no way a substitute for a medical professional’s independent judgment and should not be considered medical advice.
ويستند معظم المحتوى هنا على مراجعة المصادر. وفي مجالات عدم اليقين يُعتمد الرأي المهني. هذه المبادئ التوجيهية هي وثيقة عمل تعكس حالة الحقل في وقت النشر. وبسبب توقع حدوث تغييرات سريعة في هذا المجال لا بد من إجراء تنقيحات دورية. ويتم تشجيع المهنيين الطبيين على استخدام هذه المعلومات جنبا إلى جنب مع وليس كبديل عن أفضل قرار أو رأي سريري لهم. وقد لا تكون التوصيات المقدمة مناسبة في جميع الحالات. يجب اتخاذ أي قرار من قبل الأطباء الممارسين لتطبيق هذه المبادئ التوجيهية في ضوء الموارد المحلية والظروف الفردية.
Most of the content herein is based on literature reviews. In areas of uncertainty, professional judgment was applied. These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revisions are inevitable. Medical professionals are encouraged to use this information in conjunction with, and not as a replacement for, their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual circumstances.
أسماء شركات صناعة الأدوية العملاقة التي يرتبط رئيسي وأعضاء الجمعية الأمريكية لأطباء الغدد الصماء السريريين والكلية الأمريكية لطب الغدد الصماء الذين قاموا بإعداد هذه الخطوط التوجيهية بمصالح مادية معها أي لديهم مصالح مادية تحت عناوين ووظائف مختلفة:
BI-Lilly,
AstraZeneca (Bristol Myers Squibb),
Novo Nordisk,
Amgen,
Merck,
Sanofi Regeneron ,
Amgen,
Amarin,
Boehringer Ingelheim (BI),
Eli Lilly,
Eisai,
Intarcia ,
Amari,
Janssen BI,
Esperion,
Grifols,
Hamni,
GlaxoSmithKline (GSK),
Lexicon,
Takeda,
Johnson & Johnson,
Novartis ,
Allergan,
Pfizer,
Zimmer Biomet ,
Alexion,
Aralez, Arisaph,
Kowa, Merck,
Regeneron,
Sanofi-Aventis,
PTS Diagnostics,
Alexion,
Kastle,
Sanofi-Aventis,
Takeda,
Aegerion,
Pamlabs,
Abbott,
Endo Barrier,
Bayer,
Gilead,
Lexicon,
Medtronic,
Abbott Nutrition International,
Ionis,
Orexigen
أسماء والشهادات العلمية لرئيسي وأعضاء هاتين الجمعيتين الذين قاموا بإعداد هذه الخطوط التوجيهية:
Paul S. Jellinger, MD, MACE, Chair1 ; Yehuda Handelsman MD, FACP, FACE, FNLA, Co-Chair2 ; Paul D. Rosenblit, MD, PhD, FNLA, FACE14; Zachary T. Bloomgarden, MD, MACE4 ; Vivian A. Fonseca, MD, FACE8 ; Alan J. Garber, MD, PhD, FACE9 ; George Grunberger, MD, FACP, FACE10; Chris K. Guerin, MD, FNLA, FACE11; David S. H. Bell, MD, FACP, FACE3 ; Jeffrey I. Mechanick, MD, FACP, FACE, FACN, ECNU12; Rachel Pessah-Pollack, MD, FACE13; Kathleen Wyne, MD, PhD, FNLA, FACE16; Donald Smith, MD, MPH, FACE15; Eliot A. Brinton, MD, FAHA, FNLA5 ; Sergio Fazio, MD, PhD7 and Michael Davidson, MD, FACC, FACP, FNLA6 DISCLOSURE
فيما يلي إفصاح رئيس وكافة اعضاء الجمعية الأمريكية لأطباء الغدد الصماء السريريين والكلية الأمريكية لطب الغدد الصماء ممن قاموا بإعداد هذه الخطوط التوجيهية عن طبيعة المصالح المادية التي تربطهم مع شركات صناعة الأدوية وبضمنها الأدوية التي تستعمل في معالجة إضطراب الدهون في الدم والتي تشكل جوهر هذه الخطوط التوجيهية.
Chair Dr. Paul S. Jellinger reports that he has received speaker honoraria from BI-Lilly, AstraZeneca, Novo Nordisk, Amgen, and Merck. Task Force Members Dr. Donald A. Smith reports that he has received research grant support from Sanofi Regeneron and Amgen. Dr. Yehuda Handelsman reports that he is a consultant for Amarin, Amgen, AstraZeneca, Boehringer Ingelheim (BI), Janssen, Eli Lilly, Eisai, Intarcia, Merck, Novo Nordisk, Sanofi, and Regeneron. He is a speaker for Amarin, Amgen, AstraZeneca, BI-Lilly, Janssen, Novo Nordisk, Sanofi, and Regeneron. Dr. Handelsman has received research grant support from Amgen, AstraZeneca, BI, Esperion, Grifols, Hamni, GSK, Lexicon, Merck, Novo Nordisk, and Sanofi. Dr. David S. H. Bell reports that he is a consultant and speaker for AstraZeneca, Takeda, Janssen, and Novo Nordisk. Dr. Zachary T. Bloomgarden reports that he is a consultant for AstraZeneca, Johnson & Johnson, Merck, Intarcia, and Novartis. He is also a speaker for Merck, AstraZeneca, and Johnson & Johnson. He is a shareholder in Allergan, Pfizer, Zimmer Biomet, and Novartis. Dr. Eliot Brinton reports that he is a consultant for Alexion, Amarin, Aralez, Arisaph, AstraZeneca, Kowa, Merck, Regeneron, Sanofi-Aventis, and PTS Diagnostics. He is also a speaker for Alexion, Amarin, Amgen, Boehringer Ingelheim, Janssen, Kastle, Kowa, Merck, Novo Nordisk, Sanofi-Aventis, Takeda, and Regeneron. Dr. Michael H. Davidson reports that he is a consultant for Amgen, Regeneron, Sanofi, Merck, and AstraZeneca. He has also received speaker honoraria and has served on the speaker’s bureau for Amgen, Regeneron, and Sanofi. Dr. Sergio Fazio reports that he is a consultant for Amgen, Sanofi, Amarin, Aegerion, and Kowa. Dr. Vivian A. Fonseca reports that he is a consultant for Takeda, Novo Nordisk, Sanofi, Eli Lilly, Pamlabs, AstraZeneca, Abbott, Boehringer Ingelheim, Janssen, and Intarcia. He is also a speaker for Takeda, AstraZeneca, and Sanofi. Dr. Fonseca has received research grants from Novo Nordisk, Asahi, Eli Lilly, Abbott, Endo Barrier, Bayer, and Gilead. Dr. Alan J. Garber reports that he is a consultant for Novo Nordisk and Intarcia. Dr. George Grunberger reports that he has received speaker honoraria from Eli Lilly, BI-Lilly, Novo Nordisk, Sanofi, Janssen, and AstraZeneca. He has received research funding from AstraZeneca, Eli Lilly, Lexicon, and Medtronic. Dr. Chris Guerin reports that he is a consultant for Janssen and a speaker for Novo Nordisk. Dr. Jeffrey Mechanick reports that he is a consultant for Abbott Nutrition International. Dr. Rachel Pessah-Pollack reports that she is a consultant and speaker for Boehringer Ingelheim/Eli Lilly. Dr. Paul D. Rosenblit reports that he is a consultant for AstraZeneca and a speaker for AstraZeneca (Bristol Myers Squibb), Boehringer Ingelheim, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, and Takeda. He has also received research grant support from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Ionis, Eli Lilly, Lexicon, Merck, Novo Nordisk, Orexigen, Pfizer, and Sanofi. Dr. Kathleen Wyne reports that she is a consultant for Novo Nordisk and Abbvie. She has also received speaker honoraria from Roche and Bayer and research grant support from Sanofi and Eli Lilly.